Publications

MoTriColor publications

Project publications will be available in this section as open access.

 

MoTriColor in the acknowledgment

  1. Arena S, Siravegna G, Mussolin B, Kearns JD, Wolf BB, Misale S, Lazzari L, Bertotti A, Trusolino L, Adjei AA, Montagut C, Di Nicolantonio F, Nering R, Bardelli A. MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations. Sci Transl Med. 2016 Feb 3;8(324):324ra14. doi: 10.1126/scitranslmed.aad5640.
  2. Amatu A, Barault L, Moutinho C, Cassingena A, Bencardino K, Ghezzi S, Palmeri L, Bonazzina E, Tosi F, Ricotta R, Cipani T, Crivori P, Gatto R, Chirico G, Marrapese G, Truini M, Bardelli A, Esteller M, Di Nicolantonio F, Sartore-Bianchi A, Siena S. Tumor MGMT promoter hypermethylation changes over time limit temozolomide efficacy in a phase II trial for metastatic colorectal cancer. Ann Oncol. 2016 Jun;27(6):1062-7. doi: 10.1093/annonc/mdw071. Epub 2016 Feb 24.
  3. Oddo D, Sennott EM, Barault L, Valtorta E, Arena S, Cassingena A, Filiciotto G, Marzolla G, Elez E, van Geel RM, Bartolini A, Crisafulli G, Boscaro V, Godfrey JT, Buscarino M, Cancelliere C, Linnebacher M, Corti G, Truini M, Siravegna G, Grasselli J, Gallicchio M, Bernards R, Schellens JH, Tabernero J, Engelman JA, Sartore-Bianchi A, Bardelli A, Siena S, Corcoran RB, Di Nicolantonio F. Molecular landscape of acquired resistance to targeted therapy combinations in BRAF mutant colorectal cancer. Cancer Res. 2016 Aug 1;76(15):4504-15. doi: 10.1158/0008-5472.CAN-16-0396. Epub 2016 Jun 16.
  4. Pietrantonio F, Vernieri C, Siravegna G, Mennitto A, Berenato R, Perrone F, Gloghini A, Tamborini E, Lonardi S, Morano F, Picciani B, Busico A, Volpi CC, Martinetti A, Battaglin F, Bossi I, Pellegrinelli A, Milione M, Cremolini C, Di Bartolomeo M, Bardelli A, de Braud F. Heterogeneity of acquired resistance to anti-EGFR monoclonal antibodies in patients with metastatic colorectal cancer. Clin Cancer Res. 2017 May 15;23(10):2414-2422. doi: 10.1158/1078-0432.CCR-16-1863. Epub 2016 Oct 25.
  5. Van Emburgh BO, Arena S, Siravegna G, Lazzari L, Crisafulli G, Corti G, Mussolin B, Baldi F, Buscarino M, Bartolini A, Valtorta E, Vidal J, Bellosillo B, Germano G, Pietrantonio F, Ponzetti A, Albanell J, Siena S, Sartore-Bianchi A, Di Nicolantonio F, Montagut C, Bardelli A. Acquired RAS or EGFR mutations and duration of response to EGFR blockade in colorectal cancer. Nat Commun. 2016 Dec 8;7:13665. doi: 10.1038/ncomms13665.
  6. Fuji T, Barzi A, Sartore-Bianchi A, Cassingena A, Siravegna G, Karp D, Piha-Paul S, Subbiah V, Tsimberidou AM, Huang H, Veronese S, Di Nicolantonio F, Pingle SC, Vibat CR, Hancock S, Berz D, Melnikova VO, Erlander MG, Luthra R, Kopetz S, Meric-Bernstam F, Siena S, Lenz HJ, Bardelli A, Janku F. Mutation-Enrichment Next-Generation Sequencing for Quantitative Detection of KRAS Mutations in Urine Cell-Free DNA from Patients with Advanced Cancers. Clin Cancer Res. 2017 Jan 17. doi: 10.1158/1078-0432.CCR-16-2592. [Epub ahead of print]
  7. Bardelli A, Pantel K. Liquid biopsies, what we do not know (yet). Cancer Cell. 2017 Feb 13;31(2):172-179. doi: 10.1016/j.ccell.2017.01.002.
  8. Russo M, Bardelli A. Lesion-Directed Therapies and Monitoring Tumor Evolution Using Liquid Biopsies. Cold Spring Harb Perspect Med. 2017 Feb 1;7(2). pii: a029587. doi: 10.1101/cshperspect.a029587.
  9. Rodrigo Dienstmann, Louis Vermeulen, Justin Guinney, Scott Kopetz, Sabine Tejpar, and Josep Tabernero. Consensus Molecular Subtyping and the Evolution of Precision Medicine in Colorectal Cancer. Nat Rev Cancer. 2017 Feb;17(2):79-92. doi: 10.1038/nrc.2016.126. Epub 2017 Jan 4.
  10. Picco G, Petti C, Centonze A, Torchiaro E, Crisafulli G, Novara L, Acquaviva A, Bardelli A, Medico E. Loss of Axin1 drives acquired resistance to WNT pathway blockade in colorectal cancers cells carrying RSPO3 fusions. EMBO Mol Med. 2017 Mar;9(3):293-303. doi: 10.15252/emmm.201606773.
  11. Siravegna G, Sartore-Bianchi A, Mussolin B, Cassingena A, Amatu A, Novara L, Buscarino M, Corti G, Crisafulli G, Bartolini A, Tosi F, Erlander M, Di Nicolantonio F, Siena S, Bardelli A. Tracking a CAD-ALK gene rearrangement in urine and blood of a colorectal cancer patient treated with an ALK inhibitor. Ann Oncol. 2017 Mar 24. doi: 10.1093/annonc/mdx095. [Epub ahead of print]
  12. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies in the management of cancer. Nat Rev Clin Oncol. 2017 Mar 2. doi: 10.1038/nrclinonc.2017.14. [Epub ahead of print]